Fenwick & West represented Propeller Health, a leading digital therapeutics company dedicated to providing connected health solutions for people living with chronic obstructive pulmonary disease (COPD) and asthma, in its acquisition by ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, for $225 million.
The acquisition of Propeller establishes ResMed as a leader in COPD patient management across all stages of the disease. Following the acquisition, Propeller will continue to operate as a standalone business within ResMed’s Respiratory Care portfolio. More information about Propeller’s $225 million acquisition by ResMed can be obtained from the company announcement.
The Fenwick transaction team included corporate lawyers Michael Esquivel, Ethan Skerry, Victoria Lupu, Patrick Grilli, Jeff Zhang, Joanna Xu; executive compensation and employee benefits lawyers Matthew Cantor and Sarah Ghulamhussain; technology transactions lawyers Stefano Quintini, Spencer Glende, Andrew Whitehead, Floris de Wit, Jefferson Lin, Lael Bellamy, Karen Graefin vom Hagen and Shitel Chanana; and tax lawyers Will Skinner and Michael Knobler.